T-cell agonists in cancer immunotherapy
Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T...
Saved in:
| Main Authors: | Gennaro Ciliberto, Aung Naing, Joud Hajjar, Cara L Haymaker, Yeonjoo Choi, Yaoyao Shi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000966.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Strategies for improving the management of immune-related adverse events
by: James L Gulley, et al.
Published: (2020-10-01) -
Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors
by: Jonathan L Curry, et al.
Published: (2025-08-01) -
STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
by: Laura Gehrcken, et al.
Published: (2025-05-01) -
Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy
by: Xiaoyan Qi, et al.
Published: (2024-12-01) -
Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective
by: Lixian Yang, et al.
Published: (2025-08-01)